乌司他丁治疗慢加急性肝衰竭的回顾性队列研究

肝脏 ›› 2021, Vol. 26 ›› Issue (7): 776-778.

乌司他丁治疗慢加急性肝衰竭的回顾性队列研究

张秀翠, 李铭龙, 杭小锋, 魏博

200003 上海长征医院(杭小锋,魏博,张秀翠);青岛西海岸新区人民医院(李铭龙)

收稿日期:2021-01-28 出版日期:2021-07-31 发布日期:2021-09-02
通讯作者: 魏博,Email:weibo0816@163.com
基金资助:
国家自然科学基金(31500141),上海市科委医学引导支撑项目(17411972300)

The role of ulinastatin in the treatment of acute-on-chronic liver failure: a retrospective cohort study

ZHANG Xiu-cui¹, LI Ming-long², HANG Xiao-feng¹, WEI Bo¹

1. The Department of Infectious Diseases, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China;
2. The Department of Infectious Diseases, Qingdao Xi coast new area people's Hospital, Shandong 266400, China

Received:2021-01-28 Online:2021-07-31 Published:2021-09-02
Contact: WEI Bo, Email: weibo0816@163.com

摘要/Abstract

摘要： 目的探讨乌司他丁治疗慢加急性肝衰竭的疗效。方法采用单中心回顾性队列研究设计,对2015年1月至2016年12月间住院的慢加急性肝衰竭患者通过回顾性调查建立研究队列。共90例患者纳入队列研究,其中常规治疗组60例(对照组),常规治疗基础上加用乌司他丁组30例(试验组),该队列纳入患者无明显的统计学差异。结果在慢加急性肝衰竭患者中,实验组患者的治疗效果明显高于对照组(70% vs 45%, P=0.025),其累积肝病死亡率也明显低于对照组(27.6% vs 51.9%, P=0.0487)。自发性细菌性腹膜炎的发生率显著降低(26.67％vs 50.00％,P=0.0346),而其他并发症的发生率无统计学差异(P>0.05)。结论在治疗慢加急性肝衰竭过程中加入乌司他丁可显著改善患者的预后及降低死亡率,同时降低自发性细菌性腹膜炎的发生率。然而,进一步的前瞻性研究有待实施,以验证乌司他丁在治疗肝衰竭中的功效。

关键词: 乌司他丁, 慢加急性肝衰竭, 疗效, 自发性腹膜炎

Abstract: Objective To investigate the efficacy of ulinastatin in the treatment of acute-on-chronic liver failure (ACLF). Methods Ninty patients with ACLF admitted to our hospital from January 2015 to December 2016 were enrolled in our single-center retrospective cohort study. The patients were divided into control group (treated with routine therapy) and experimental group (treated with ulinastatin added to routine therapy). There was no significant difference in demographics between the 2 groups. Results The therapeutic efficacy in the experimental group was significantly better than the control group (70% vs 45%, P=0.025), and the mortality rate was lower than the control group (27.6% vs 51.9%, P=0.0487). The incidence of spontaneous bacterial peritonitis was significantly lower in the experimental group (26.67% vs 50.00%, P=0.0346), while the rates of other complications had no statistical difference (P>0.05). Conclusion Ulinastatin added to routine therapy can improve the prognosis and reduce the incidence of spontaneous bacterial peritonitis in ACLF patients. Further prospective studies are warranted to verify the efficacy of ulinastatin in the treatment of liver failure.

Key words: Ulinastatin, Acute-on-chronic liver failure, Efficacy, Spontaneous bacterial peritonitis

张秀翠, 李铭龙, 杭小锋, 魏博. 乌司他丁治疗慢加急性肝衰竭的回顾性队列研究[J]. 肝脏, 2021, 26(7): 776-778.

ZHANG Xiu-cui, LI Ming-long, HANG Xiao-feng, WEI Bo. The role of ulinastatin in the treatment of acute-on-chronic liver failure: a retrospective cohort study[J]. Chinese Hepatolgy, 2021, 26(7): 776-778.

参考文献

[1] Mehta G, Mookerjee RP, Sharma V, et al. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. Liver Int, 2015,35:724-734.
[2] Kubes P, Mehal WZ,et al. Sterile inflammation in the liver. Gastroenterology, 2012,143:1158-1172.
[3] Wang LZ, Luo MY, Zhang JS, et al. Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis. Int J Clin Pharmacol Ther, 2016,54:890-898.
[4] Wang FY, Fang B, Qiang XH, et al. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin alpha1 for Sepsis: A Systematic Review and Meta-Analysis. Biomed Res Int, 2016,2016:9508493.
[5] Li X, Li J, Ou YJ, et al. Hepatoprotective effect of ulinastatin in a rat model of major hepatectomy after obstructive jaundice. Dig Dis Sci, 2015,60:1680-1689.
[6] Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int, 2014,8:453-471.
[7] Liver Failure And Artificial Liver Group, Chinese Society Of Infectious Disease,CMA; Severe Liver Disease And Artificial Liver Group, Chinese Society Of Hepatology,CMA.Diagnostic and treatment guidelines for liver failure (2012 version). Zhonghua Gan Zang Bing Za Zhi, 2013,21:177-183.
[8] Lin SD, Endo R, Kuroda H, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with chronic liver diseases and hepatocellular carcinoma. J Gastroenterol Hepatol, 2004,19:327-332.
[9] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014,60:250-256.
[10] Dhiman RK, Makharia GK, Jain S, et al. Ascites and spontaneous bacterial peritonitis in fulminant hepatic failure. Am J Gastroenterol, 2000,95:233-238.
[11] Khot AA, Somani P, Rathi P, et al. Prognostic factors in acute-on-chronic liver failure: a prospective study from western India. Indian J Gastroenterol, 2014,33:119-124.
[12] Li Y, Zhao L, Fu H, et al. Ulinastatin suppresses lipopolysaccharide induced neuro-inflammation through the downregulation of nuclear factor-kappaB in SD rat hippocampal astrocyte. Biochem Biophys Res Commun, 2015,458:763-770.
[13] Wu YJ, Ling Q, Zhou XH, et al. Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation. Hepatobiliary Pancreat Dis Int, 2009,8:53-58.
[14] Chen X, Wang Y, Luo H, et al. Ulinastatin reduces urinary sepsisrelated inflammation by upregulating IL10 and downregulating TNFalpha levels. Mol Med Rep, 2013,8:29-34.
[15] Huang N, Wang F, Wang Y, et al. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis. J Surg Res, 2013,182:296-302.
[16] Bajaj JS, O'Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014,60:250-256.